5413-85-4Relevant academic research and scientific papers
Photochemical synthesis method of heteroarylamine compounds
-
Paragraph 0068, (2020/10/14)
The invention provides a photochemical synthesis method of heteroarylamine compounds. The photochemical synthesis method comprises the following steps: S1, mixing raw materials including heteroaryl nitro compounds, a solvent and a photocatalyst to obtain a mixture; and S2, carrying out a photocatalytic reduction reaction on the mixture under an illumination condition to obtain a product system containing the heteroarylamine compounds. According to the photochemical synthesis method, photocatalytic reduction of various different heteroaryl nitro compounds is achieved under the illumination condition, and the high-yield heteroaryl amine compounds are obtained. The photocatalyst is an existing common catalyst, has no strict requirements on equipment and is easy to recover, and the safety riskof the heteroarylamine compound and the catalyst cost are reduced. Any metal reagent and reducing agent do not need to be added in the whole reaction process of photocatalysis, the reaction conversion rate is high, and post-treatment is simple and easy to operate, so the method is safer and more environmentally friendly.
Design, synthesis and in vitro cytotoxic activity of new 6,9-disubstituted purine analogues
Atalay, Rengul Cetin,Guven, Ebru Bilget,Kucukdumlu, Asligul,Tuncbilek, Meral
, p. 70 - 82 (2020/03/30)
A series of new 6,9-disubstituted purine analogs with 4-substituted piperazine at C-6 and 4-substituted benzyl at N-9 were designed and synthesized in four steps. All synthesized compounds (7-26) were screened initially for their in vitro anticancer activity on Huh7 liver, HCT116 colon and MCF7 breast carcinoma cell lines. Cytotoxic bioactivity studies revealed that all compounds screened, with compound 19 being the exception, were found to have promising cytotoxic activities at IC50 range of 0.05-21.8 μM against cancer cells Huh7, HCT116 and MCF7. Among the prepared purine analogs, two of them (12 and 22) exhibited excellent cytotoxic activities, with IC50 0.08-0.13 μM, on Huh7 cells comparable to camptothecin (CPT) and better than cladribine, fludarabine and 5-FU. Afterwards, the evaluation of cytotoxicity of the most potent purine analogs was screened against further hepatocellular cancer (HCC) cell lines. The 6-(4-(4-trif-luoromethylphenyl)piperazine (12) and 6-(4-(3,4-dichlorophenyl)piperazine analogs (25) displayed a significant IC50 values (IC50 0.1-0.13 μM) comparable to CPT and better cytotoxic bioactivity when compared with 5-FU, cladribine and fludarabine on HCC cells (Huh7 and HepG2).
Preparation method for catalyzing pyrimidine cyclic hydroxyl chlorination by tetraethylammonium chloride
-
Paragraph 0028-0031, (2020/04/17)
The invention discloses a preparation method for catalyzing pyrimidine cyclic hydroxyl chlorination by tetraethylammonium chloride, which comprises the following steps: (1) adding phosphorus oxychloride into a container, adding tetraethylammonium chloride as a catalyst, adding a pyrimidine cyclic hydroxyl compound, and heating to react; (2) preparing an alkali liquor, cooling to 0 DEG C, and slowly dropwise adding an obtained reaction liquid into the alkali liquor for quenching to obtain a target product. The method has the advantages that the provided pyrimidine cyclic hydroxyl chlorination catalysis method is small in environmental pollution, the obtained product is light in color, the catalysis efficiency is high, and the phosphorus oxychloride recovery pressure is small.
Synthesis and herbicidal evaluation of aryloxyphenoxypropiona te derivatives containing purine moiety
Shi, Jianjun,Ren, Guihua,Dai, Zhimeng,Wu, Ningjie,Weng, Jianquan,Xu, Tianming,Liu, Xinghai,Tan, Chengxia
, p. 15 - 20 (2018/02/14)
series of purinoxyphenoxypropionates were designed and synthesized by introducing 8-(trifluoromethyl)-9H-purine into the aryloxyphenoxypropionate backbone. Methods: The products were characterized by 1H NMR and HRMS. Results and Conclusion: Preliminary bioassays indicated that most of the compounds exhibited good herbicidal activity at 200 mg/L.
Synthesis and biological evaluation of novel 6,11-dihydro-5H-benzo[e]pyrimido- [5,4-b][1,4]diazepine derivatives as potential c-Met inhibitors
Huang, Daowei,Huang, Lei,Zhang, Qingwei,Li, Jianqi
, p. 212 - 228 (2017/09/23)
Over expression of c-Met tyrosine kinase is known to promote tumorigenesis and metastasis, as well as to cause therapeutic resistance. Herein a series of novel 6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepine derivatives were designed, synthesised and evaluated for their c-Met kinase inhibition. Compounds 17e, 17f, 18a, and 18b were further examined for their anti-proliferative activities against four typical cancer cell lines (PC-3, Panc-1, HepG2, and Caki-1). The promising compound 17f was identified as a multi-target receptor tyrosine kinase inhibitor, which also displayed favourable pharmacokinetic properties in rats, had an acceptable safety profile in preclinical studies, and significant anti-tumour activity in the Caki-1 tumour xenograft model.
1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS
-
Paragraph 0290, (2017/02/09)
The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof has an EP4 receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of EP4 receptor associated diseases (e.g., rheumatoid arthritis, aortic aneurysm (e.g. abdominal aortic aneurysm, thoracic aortic aneurysm, thoracoabdominal aortic aneurysm etc.), endometriosis, ankylosing spondylitis, inflammatory breast cancer etc.) and the like.
CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE
-
Paragraph 0218, (2017/10/11)
Disclosed are cyclic-di-nucleotide cGAMP analogs, methods of synthesizing the compounds, pharmaceutical compositions comprising the compounds thereof, and use of compounds and compositions in medical therapy.
Development of dichloroacetamide pyrimidines as pyruvate dehydrogenase kinase inhibitors to reduce cancer cell growth: Synthesis and biological evaluation
Zhang, Shao-Lin,Zhang, Wen,Xiao, Qingpin,Yang, Zheng,Hu, Xiaohui,Wei, Zhiyi,Tam, Kin Yip
, p. 78762 - 78767 (2016/09/09)
Pyruvate dehydrogenases kinases (PDKs) have recently emerged as an attractive target for anticancer treatment. Herein, we report the synthesis and biological evaluation of novel PDK1 inhibitors as anticancer agents. Of the newly synthesized compounds, N-(4,6-bis(4-(2-hydroxyacetyl)piperazin-1-yl)-2-methylpyrimidin-5-yl)-2,2-dichloroacetamide (40) is found to inhibit the growth of SF188 cancer cells with an IC50 value of 8.21 M. Isothermal titration calorimetry (ITC) experiments reveal that compound 40 directly binds to PDK1 with a Kd value of 14.7 M. Compound 40 inhibits PDK1 activity by 72.5% at a concentration of 40 , meaning it could be a useful compound to explore the pharmacology of PDK1.
IRAK INHIBITORS AND USES THEREOF
-
Paragraph 00297; 00298; 00299, (2015/04/15)
The present invention provides compounds, compositions thereof, and methods of using the same.
PROCESS FOR THE PREPARATION OF AN INTERMEDIATE FOR A TRIAZOLOPYRIMIDINE CARBONUCLEOSIDE
-
Paragraph 0160 - 0162, (2015/06/10)
A process for the preparation of 4,6-dihalopyrimidin-5-amines of formula (II), or salts thereof, which comprises reacting 5-aminopyrimidin-4,6-diols of formula (III), or salts thereof, or a solvate either of the compound of formula (III) or of a salt thereof, with a halogenating agent, new intermediates useful in the preparation of the compound of formula (II) and processes for the preparation of these intermediates. The invention also refers to a process for the preparation of ticagrelor or a pharmaceutically acceptable salt thereof from 4,6-dihalo-2-(propylthio)pyrimidin-5-amine of formula (IIA).
